International Net Income from 2010 to 2025

IBT Stock   694.00  2.00  0.29%   
International Biotechnology's Net Income is decreasing over the years with very volatile fluctuation. Overall, Net Income is expected to go to about 46.9 M this year. During the period from 2010 to 2025 International Biotechnology Net Income annual values regression line had coefficient of variation of  101.99 and r-squared of  0. View All Fundamentals
 
Net Income  
First Reported
2004-01-31
Previous Quarter
28.3 M
Current Value
10.5 M
Quarterly Volatility
15.9 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check International Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among International Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 2.7 M, Selling General Administrative of 1.1 M or Total Revenue of 48.5 M, as well as many indicators such as . International financial statements analysis is a perfect complement when working with International Biotechnology Valuation or Volatility modules.
  
This module can also supplement various International Biotechnology Technical models . Check out the analysis of International Biotechnology Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in International Stock

International Biotechnology financial ratios help investors to determine whether International Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in International with respect to the benefits of owning International Biotechnology security.